Osiris Therapeutics Inc (NASDAQ:OSIR)
During the Trading Day
| 10.70 |  -0.57 / -5.06% |
Data as of 4:00pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 10.70 |  0.00 / 0.00% |
Volume: 0.00 |
Latest OSIR News | Press Releases
| Pipeline Progress at Gilead - Analyst Blog May 16 / Zacks.com | Osiris Loss In-Line with Expectations - Analyst Blog May 08 / Zacks.com |
Today’s Trading
| Previous close | 11.27 |
| Today’s open | 11.27 |
| Day’s range | 10.65 - 11.31 |
| Volume | 124,758 |
| Average volume (3 months) | 140,580 |
| Market cap | $371.1M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/20/2013
Growth & Valuation
| Earnings growth (last year) | -175.56% |
| Earnings growth (this year) | +10.29% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -72.16% |
| P/E ratio | NM |
| Price/Sales | 25.00 |
| Price/Book | 10.33 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CRISCuris Inc | -0.21 | -5.10% |
| NVAXNovavax Inc | -0.03 | -1.49% |
| HPTXHyperion Therapeutic... | -0.69 | -3.09% |
| PLXProtalix Biotherapeu... | +0.04 | +0.78% |
Data as of 4:02pm ET, 05/20/2013
Financials
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.09 |
| Annual revenue (last year) | $11.8M |
| Annual profit (last year) | -$11.1M |
| Net profit margin | -93.74% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman Peter A. Friedli |
President, Chief Executive Officer & Director Charles Randal Mills, PhD |
Corporate headquarters Columbia, Maryland |
Forecasts
